Abstract submission

Submit your abstract now

Abstract submission is an important part of this meeting.

As a participant, you’ll have the opportunity to submit an abstract and (if it’s accepted) have the possibility to discuss it with the international faculty and your peers.

Submitting an abstract constitutes a formal commitment to attend the meeting in Palma de Mallorca, Spain (should the abstract be accepted). If requested, you must also present the work as an oral or poster presentation during the assigned session and time slot in the scientific program.

Joint Fellowship Awards

We’re excited to announce that this year’s meeting will include the 6th Emerging Investigators EBMT-EHA Joint Fellowship Awards in the Field of Cell Therapy and Immunotherapy. The Scientific Program Committee (SPC) will select three young investigators, each of whom will receive €10,000.

For more information, read EBMT’s Joint Fellowship Awards guidance (PDF, 195 KB).

Registration

If you’re presenting an abstract or case orally, you’ll be eligible for early bird registration discount fee. You’ll receive the details in your acceptance letter.

All other authors who wish to take advantage of this fee should complete their registration before December 8, 2025 (23:59 CET).

For further details, visit our registration page.

Submission procedure

The abstracts / clinical cases submitted via the submission portal will be reviewed and allocated by the SPC.

Regular abstract/clinical case submission

  • The submission period for regular abstracts/clinical cases is July 10, 2025, to November 16, 2025 (23:59 CET).
  • Authors will be informed about the allocation by November 26, 2025.

Late-breaker abstract/clinical case submission

This is an opportunity to submit groundbreaking, high-impact research with recent, time-sensitive data that could not have been available during the regular submission period.

It is not intended for work delayed due to time constraints, but for studies with the potential to significantly influence practice or advance science.

  • The submission period for late-breaking abstracts/clinical cases is January 1, 2026, to January 11, 2026 (23:59 CET).
  • Authors will be informed about the allocation by January 19, 2026.

If you have any questions about abstract submission or terms, please contact education.events@ebmt.org.

Guidelines for abstract/clinical case submission

Before you submit an abstract, you should read the following guidelines.

  • Text should be a maximum of 400 words.
  • Abstracts can be structured (e.g. ‘Objectives,’ ‘Methods,’ ‘Results,’ ‘Conclusions’).
  • Images must be submitted as JPEG, TIF, or GIF files.
  • Due to limited space, only a simple graph/image can be submitted.
  • Image files should not exceed 500 KB.
  • Tables should be created as so.
  • You must mention all the authors and include disclosures and affiliations. There is no limit to the number of authors.
  • References are obligatory when submitting an abstract or clinical case.

Abstract and clinical case submission topics

  • Access to CAR T
  • Advanced Practice Roles within the Multidisciplinary team in CAR T Therapy
  • CAR-based Cellular Therapy—Clinical: Biomarkers for CAR T efficacy and prediction model for response and toxicity
  • CAR-based Cellular Therapy—Clinical: Challenges of CAR-based cellular therapy (bridging therapies and lymphodepletion), and clinical indication
  • CAR-based Cellular Therapy—Clinical: Clinical investigations into therapeutic applications of CAR-T cell in oncology and other fields, adult/pediatric indications
  • CAR-based Cellular Therapy—Clinical: Management of toxicities (early and late)
  • CAR-based Cellular Therapy—Preclinical: CAR T cell manufacturing methodologies
  • CAR-based Cellular Therapy—Preclinical: Innovative T cell engineering, CAR designs, and optimization of CAR T cell function
  • CAR-based Cellular Therapy—Preclinical: Mechanistic studies of CAR T efficacy and toxicities, and tumor resistance
  • CAR-based Cellular Therapy—Preclinical: Novel in vivo and in vitro models to functionally evaluate CAR T cells
  • Clinical case on multiple myeloma
  • Clinical case on new technologies for CAR T development
  • Clinical case on solid tumors
  • Models of Care and Multidisciplinary Collaboration in CAR T Programs
  • Perspectives in Adolescent and Young Adult (AYA) CAR T Care
  • Quality of Life
  • Real-world Nursing Practice in CAR T-cell Therapy
  • Symptom Management and Toxicity Monitoring in CAR T Patients
Share